The Next Frontier for Accessible Medicines

The rising cost of medicines remains one of the most pressing challenges for patients and the healthcare industry. In Washington D.C., The Atlantic convened a distinguished panel titled The Next Frontier for Accessible Medicines. The discussion explored how to ensure high-quality, affordable medicines for all—focusing on the role of generics and biosimilars and how industry leaders are responding to evolving pressures in the market. Speakers included John Murphy III (President & CEO, Association for Accessible Medicines), Molly Cox (SVP of Partnerships, The Atlantic), Senator Ben Ray Luján (New Mexico), Alex Keeton (Executive Director, Biosimilars Council & Senior VP, Policy, AAM), Matthew Erick (Chief Commercial Officer, Biocon Biologics), Kimberly Maxfield (Head of U.S. Regulatory Affairs, Biocon Biologics) and Kelly Anderson (Assistant Professor & Investigator, Program on Regulation, Therapeutics & Law at Harvard & Brigham Women’s) among others.